#China #ADC #Kelun-Biotech #Sacituzumab #Kunming

Kelun-Biotech's Significant Contributions at the 2025 CCHIO Congress

The 2025 Chinese Congress on Holistic Integrative Oncology (CCHIO) took place from November 6 to 9 in the picturesque city of Kunming, Yunnan. This prominent event was a collaborative effort organized by the Chinese Anti-Cancer Association (CACA), among others, to bring together experts, scholars, and academicians from all over China to discuss advancements in cancer diagnosis and treatment. One of the standout presentations at this congress came from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., which showcased results from multiple clinical studies centered on their innovative product, TROP2 ADC sacituzumab tirumotecan (sac-TMT).

Focus on Endometrial Cancer

On November 7, Professor Sheng Jindong from Tianjin Cancer Hospital presented the findings from a Phase II clinical trial evaluating the efficacy and safety of sacituzumab tirumotecan monotherapy in patients with locally advanced or metastatic endometrial cancer (EC). This particular study enrolled 158 patients, assigning them to two different dosage groups: a 4 mg/kg group and a 5 mg/kg group. Collectively, the results indicated a promising confirmed objective response rate (ORR) of 30.7% for the 4 mg/kg group and 34.1% for the 5 mg/kg group, all of which were classified as partial responses. Additionally, the median progression-free survival (PFS) was reported at 6.0 months for the 4 mg/kg dose and 7.3 months for the 5 mg/kg dose. Importantly, the safety profiles were consistent with expectations, leading to the initiation of two global Phase III trials aimed at further assessing sac-TMT's effectiveness in advanced EC.

Encouraging Data from Lung Cancer Trials

On November 8, clinical data was again in the spotlight as Professor Fang Wenfeng from the Cancer Center of Sun Yat-sen University shared initial results from a Phase II study investigating sac-TMT for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by uncommon EGFR mutations in previously treated patients. Out of 42 enrolled patients, an ORR of 35.7% was noted, while the disease control rate stood at an impressive 85.7%. With a median duration of response yet to be fully established, the outcome demonstrated significant hope for patients with uncommon genetic profiles, showing that sac-TMT could become a viable option for advancing treatment in challenging cases.

Meanwhile, Professor Fang also presented findings from another cohort evaluating the combination of sac-TMT and tagitanlimab as a first-line therapy for advanced non-squamous NSCLC. The results were remarkable, showing an ORR of 59.3% and a median PFS of 15 months. The analysis indicated a robust safety profile, with no new safety signals emerging, thus paving the way for further trials to confirm these favorable outcomes.

Commitment to Innovation in Oncology

With a commitment to addressing unmet medical needs, Kelun-Biotech has launched more than 30 clinical studies across various oncological applications, including lung cancer and breast cancer, highlighting their dedication to innovation in therapeutic development. The company actively employs its proprietary Antibody-Drug Conjugate (ADC) technology and the novel DC platform, OptiDC™, to advance significant clinical value in cancer treatments.

Sac-TMT, a major component of Kelun-Biotech's pipeline, has already been approved for treating specific forms of breast cancer and non-small cell lung cancer in China, positioning it as a pioneering ADC therapy globally. As the landscape of cancer treatment continually evolves, Kelun-Biotech stands out for its robust research and development efforts aimed at improving patient outcomes.

In summary, the data presented at the CCHIO serves as an optimistic outlook for both the medical community and patients battling advanced cancers. Kelun-Biotech's ongoing studies and results signify a transformative step in the oncology landscape, potentially offering new hope through innovative treatments for those in dire need.